Arlin B. Rogers Alnylam Pharmaceuticals, Cambridge, MA, USAArlin B. Rogers, DVM, PhD, DACVP
Arlin Rogers is Director of Pathology in the Department of Early Development at Alnylam Pharmaceuticals. He directs the Investigative Pathology unit charged with identifying novel molecular targets and mitigating off-target toxicity associated with RNAi therapeutics. Additionally, he assists with safety and regulatory readouts for late-stage preclinical compounds. He received his DVM from the University of Illinois, and spent three years practicing small animal and emergency medicine in Houston and Austin, Texas. He then entered a combined anatomic pathology residency/PhD training program at Colorado State University, where he performed NIH-sponsored research on vertical transmission of feline immunodeficiency virus as a model of maternal-fetal HIV-1 transmission. After receiving his PhD, Dr. Rogers joined the Division of Comparative Medicine at MIT, where he rose to the rank of Chief of Comparative Pathology. During that period, his research interests pivoted towards chronic digestive diseases with an emphasis on the role of sex in hepatitis and liver cancer. He continued his research into mechanisms of sex-dependent liver carcinogenesis at the Lineberger Comprehensive Cancer Center at the University of North Carolina for several years before being recruited to Tufts as Head of the Section of Pathology in 2013. At the Tufts-Cummings School of Veterinary Medicine he continued his independent research on the role of sex in chronic liver disease and cancer, and collaborations as a scientist and pathologist with particular reference to chronic inflammatory and neoplastic diseases of the digestive system. He also provided diagnostic biopsy and autopsy service to the Cummings Veterinary Medical Center and was the Course Director for General Pathology. Moreover, he founded and directed Tufts Discovery Pathology, a contract histopathology laboratory serving Boston-area biopharmaceutical companies and academic institutions. Dr. Rogers joined Alnylam in 2017. He is author or co-author of >100 peer-reviewed publications.